Core Insights - The article discusses the IPO progress of Aimi Biotech, a pioneer in next-generation bispecific antibodies, focusing on its innovative T cell engagers (TCE) for cancer and autoimmune disease treatment [1][2]. Group 1: Company Overview - Aimi Biotech is at the forefront of the bispecific antibody treatment field, aiming to develop TCEs globally for various cancers and autoimmune diseases [1]. - The company plans to use the net proceeds from the IPO primarily for clinical development of core products, pipeline expansion, and operational funding [1]. - Aimi Biotech has a strong leadership team with extensive industry experience, including founder Dr. Wu Chenbing and Chief Medical Officer Dr. Zhu Yonghong, which supports its strategic execution and technology transfer [2]. Group 2: Technology and Product Pipeline - Aimi Biotech has developed proprietary technology platforms, including FIT-Ig, MAT-Fab, and a CD3 antibody library, which are crucial for advancing bispecific antibody development [2][3]. - The FIT-Ig platform is unique as it does not require amino acid mutations or linker peptides, with clinical projects like EMB-01 and EMB-06 already in advanced stages [3]. - The company has established seven product pipelines covering oncology and immunology, including key products EMB-01 for colorectal cancer, EMB-06 for multiple myeloma, and EMB-07 for lymphoma and solid tumors [2]. Group 3: Market Potential and Collaborations - The global bispecific antibody market is projected to reach $221.8 billion by 2034, with a compound annual growth rate (CAGR) of 32.4% from 2024 to 2034 [1]. - Aimi Biotech has secured multiple licensing agreements since the end of 2023, with a total transaction value exceeding $2.1 billion, ranking second globally in the TCE field [4]. - The company is positioned to accelerate the commercialization of innovative drugs, enhancing its competitive edge in the rapidly growing bispecific antibody and TCE treatment markets [4].